Contact
 
News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

Advances on HIV Prevention Tools Heralded At Conference - July 23, 2010

The International AIDS Vaccine Initiative (IAVI) issued a statement on advances on HIV prevention tools at the International AIDS Conference in Vienna.  The full statement is below.

Update on the Renewed Canadian HIV Vaccine Initiative - July 21, 2010

The Honourable Leona Aglukkaq, Minister of Health in collaboration with the Bill & Melinda Gates Foundation, announced the renewed Canadian HIV Vaccine Initiative (CHVI), which features the creation of the CHVI Research and Development Alliance.  The full announcement is available here: http://www.chvi-icvv.gc.ca/index-eng.html.

WHO and UNAIDS Welcome Ground Breaking Proof Of Concept Study Results For Vaginal Gel Showing Reduced Risk of HIV Infections In Women - July 20, 2010

WHO and UNAIDS congratulate CAPRISA, a designated UNAIDS Collaborating Centre for HIV Prevention Research, on the successful completion of the study.  The full statement is available here: http://www.unaids.org/en/KnowledgeCentre/Resources/PressCentre/PressReleases/2010/20100719_PS.asp.

Statement of Anthony S. Fauci, M.D., on Results from the CAPRISA 004 Microbicide Study - July 20, 2010

The National Institute of Allergy and Infectious Diseases National Institutes of Health congratulate the Centre for the AIDS Program

Statement of Larry Corey, MD on the Success of the CAPRISA 004 Microbicide Trial - July 19, 2010

The HIV Vaccine Trials Network (HVTN) issued a statement on the CAPRISA 004 microbicide trial.  The full statement is below.

Study of Microbicide Gel Shows Reduced Risk of HIV & Herpes Infections in Women - July 19, 2010

The Centre for the AIDS Programme of Research in South Africa (CAPRISA) reports that researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses.&

AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms - July 19, 2010

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.  The full AVAC statement is available below.

Gates Foundation HIV Strategy - July 17, 2010

The Bill & Melinda Gates foundation issued a highly targeted strategy for HIV, which states that the "foundation’s number-one global health priority is discovering and introducing vaccines for infectious diseases."  Click the link below to read the full strategy. 
 

 

AVAC Report: Turning the Page to a New Era in HIV Prevention Research - July 14, 2010

A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention—and provides strategic recommendations for moving forward in a time of constrained resources and faltering commitment to ending AIDS.  The announcement is below.
 

Margaret McGlynn, Former President of Global Vaccines at Merck, Joins IAVI Board - July 6, 2010

The International AIDS Vaccine Initiative (IAVI) announces the appointment of Margaret McGlynn, former President of Global Vaccines and Anti-infectives at Merck, to its board of directors.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account